Picofy: Complete Buyer's Guide

Picofy is a dual-wavelength picosecond Nd:YAG platform manufactured by Speclipse, Inc. and marketed in the United States by InMode. The system delivers 1064nm and 532nm wavelengths.

The platform uses a solid-state Nd:YAG architecture with KTP frequency-doubled 532nm output. The two-wavelength design provides a focused core platform, but buyers seeking dedicated 755nm, 785nm, 730nm, 694nm, 650nm or 585nm channels should compare Picofy against multi-wavelength alternatives.

Picofy specifies a 300-picosecond pulse duration at both 1064nm and 532nm. InMode states a maximum peak power of up to 2.0 GW, consistent with the published maximum 605 mJ pulse energy at 1064nm over a 300 ps pulse.

The source profile also identifies thermal-lens control as a key resonator-management feature intended to preserve spot size and beam quality during higher-repetition-rate operation.

The May 2026 Special 510(k) documentation identified Array MLA 110 as the renamed prior MLA configuration and added the Peak MLA 60 handpiece with software-controlled fluence limits.

This gives Picofy a flexible fractional toolkit in addition to its conventional Zoom and Collimated delivery options.

According to the source profile, Picofy is cleared for a relatively broad aesthetic indication set that includes tattoo removal, benign pigmentation, acne scars and wrinkles.

This broader indication set distinguishes Picofy from platforms that are primarily positioned around tattoo or pigment applications. Exact treatment protocols and patient selection remain matters for appropriately trained clinicians and the applicable device labeling.

• Removal of unwanted tattoos
• Treatment/removal of benign pigmented lesions
• Treatment of acne scars
• Treatment of wrinkles

Note: Confirm the exact cleared indications and labeling for the quoted configuration before purchase or clinical use.

• 300ps pulse duration at both 1064nm and 532nm
• Up to 605mJ at 1064nm and 254mJ at 532nm
• Manufacturer-stated peak power of up to 2.0 GW
• Thermal-lens control intended to preserve spot size and beam quality during higher-repetition-rate operation
• Flexible delivery through Zoom, Collimated, Array MLA 110 and Peak MLA 60
• Broad FDA-cleared indication set including tattoos, benign pigmentation, acne scars and wrinkles
• InMode's established U.S. commercial and customer-care channel

Picofy uses a focused two-wavelength architecture of 1064nm and 532nm. Practices with significant demand for ink colors or applications that benefit from dedicated 755nm, 785nm, 730nm, 694nm, 650nm or 585nm wavelengths should compare alternative platforms.

Picofy is also a relatively new U.S. platform. The source profile notes that the Picofy model was expressly added to the FDA clearance only in May 2026, so its U.S. ownership and resale history is much shorter than that of established pico platforms.

Buyers should also confirm the electrical requirement, quoted configuration, warranty terms, service responsibilities and replacement/repair costs in writing before purchase.

Public Picofy materials do not identify a standard Picofy-specific warranty term or exclusions. Warranty terms should therefore be treated as quote-specific until confirmed in writing.

The current platform is marketed in the U.S. through InMode, with an established national customer-care channel. Buyers should clarify the respective responsibilities of Speclipse and InMode for installation, service, parts, training and escalation.